GlassScriptPhysician profile
Michael D Kassels
NPI 1245348655
$1,721.75
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,358 · 2020: $239 · 2022: $125.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $279.57 | 2019-2022 | |
| Medtronic USA, INC. | $261.99 | 2019 | |
| Lilly USA, LLC | $240.07 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $214.19 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $141.76 | 2019 | |
| Nevro Corp. | $126.63 | 2019 | |
| Sanofi-Aventis U.S. LLC | $124.95 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $124.19 | 2019 | |
| Hologic Sales and Service, LLC | $57.85 | 2020 | |
| Glaxosmithkline, LLC. | $33.30 | 2019 | |
| Amarin Pharma, INC. | $27.57 | 2019 | |
| Focal Therapeutics, INC. | $25.67 | 2019 | |
| Sanofi Pasteur INC. | $23.26 | 2019 | |
| Orthogenrx INC. | $20.39 | 2019 | |
| Astellas Pharma US INC | $20.36 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kassels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.